Long-term follow-up of PET/CT-adapted therapy after three cycles of ABVD for all stages of classic Hodgkin lymphoma: Results of the GATLA LH-05 trial.
PET scanning during early treatment reliably predicts long-term outcomes in Hodgkin lymphoma, validating therapy adjustments.
The GATLA LH-05 trial report (563 patients, all cHL stages I–IV, Argentina) provides the longest follow-up data for PET/CT-adapted ABVD treatment in classical Hodgkin lymphoma, demonstrating durable 10-year disease control comparable to more intensive approaches. PET3 Deauville score was the only independent prognostic factor, validating early PET-based treatment adaptation as standard of care regardless of initial disease stage.
What the study was
- Study design
- prospective non-randomized multicenter cohort (563 patients, median follow-up 93.5 months)
- Category
- Other
- Maturity
- Validated
- Journal
- British Journal of Haematology
Why it surfaced
Extended 10-year follow-up providing high-confidence evidence that PET-CT-adapted ABVD yields durable long-term control in all cHL stages; directly supports T1 hematologic malignancy treatment paradigms.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.